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摘要  经分子杂交技术合成了一系列 4-取代-1-（2-甲基-6-（吡啶-3-基）-烟酰）氨基脲类衍生物 4a-r。采用 MTT 法研
究了目标化合物对人肝癌细胞（QGY-7703）、人肺癌细胞（NCl-H460）和乳腺癌细胞（MCF-7）的体外抗肿瘤活性。
化合物 4n 显示了最优的活性，其半数抑制浓度（IC50）为 8.89 ～11.45 μmol/L。细胞体内的生物研究显示 4n 药物处
理能明显增加细胞体内 PARP 切割水平以及诱导 QGY-7703 肿瘤细胞的凋亡。 
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Abstract   
A series of 4-substitued-1-(2-methyl-6-(-3-pyridy)-nicotinoyl) semicarbazides 4a-r were synthesized via molecular hybridization strategy. The 
synthesized compounds (4a-r) were screened for their anticancer potential against different cancer cells viz human hepatocelular carcinoma 
(QGY-7703), non-small cell lung (NCl-H460) and human breast (MCF-7) cancer cell lines by the MTT assay. Compound 4n showed significant 
anticancer activity in these cancer cell lines with a range of IC50 values ranges from 8.89 to 11.45 μmol/L. Further biology studies showed that 4n 
treatment obviously increased the level of cleaved PARP and induced the apoptosis in QGY-7703 cells.  
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1  Introduction 
Cancer is the second most lethal disease on the earth, 15% of the world's deaths are caused by cancer in 2010
 [1]
. Although 
there are some traditional types of cancer treatments such as surgery, chemotherapy and radiation therapy, the successful 
treatment of cancer still remains a huge challenge mainly due to poor curative effect, toxic side effect, unpleasant experience 
and so on. With the progress of molecular biology, targeted tumor therapy has become a hot research topic in cancer treatment 
recently, a number of targeted drugs were approved for clinical application 
[2]
. 
It is well known that a wide range of heterocyclic molecules have shown different pharmacological properties such as 
antitubercular, anticonvulsant, antimalarial and antibacterial activities 
[3-6]
. Furthermore, some heterocyclic molecules such 
as bipyridine, pyrrole, benzimidazole, indole, benzotriazole and thienopyrimidine derivatives have shown good antitumor 
activities
 [7-12]
.  
Molecular hybridization is a new valuable structure modification method in drug design and development based on the 
combination of pharmacophoric moieties of different bioactive substances to generate a new hybrid compound with im-
proved efficacy, low toxicity and undesired side effects 
[13-14]
.  Bipyridine 
[6]
 and semicarbazides 
[15]
 have already been 
demonstrated antitumor activity, with the aim of developing antitumor candidates with improved properties, a series of 
4-substitued-1-(2-methyl-6-(-3-pyridy)-nicotinoyl) semicarbazides 4a-r (Figure 1) were designed and synthesized by the 
molecular hybridization strategy. The cytotoxicity in vitro against QGY7703, NCl-H460, and MCF7 cell lines was evaluat-
ed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. Most of such compounds have the 
ability to inhibit cancer cells proliferation and one compound 4n is the best one for QGY7703 cells inhibition with the IC50 
8.89 μM. Apoptosis is an important kind of cancer cell deaths, and the cleaved PARP is the marker of it. Further cell biolo-
gy studies showed that 4n treatment dramatically increases the cleaved PARP and induces the apoptosis in QGY7703 cells. 
So such kind of compounds can be a potential direction for anti-cancer drug development.  
 
 
 
 
 
 
 
 
Figure 1 Structures of target compounds 4a-r 
2  Results and discussion 
2.1 Synthetic chemistry 
The synthetic strategy to prepare target compounds is outlined in Scheme 1. The intermediate 
6-methyl-(2,3'-bipyridine)-5-carbohydrazide (3) was synthesized by condensation of 
3-(dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one (1) and ethyl acetoacetate with 73.5% yield, followed by reaction with 
hydrazine hydrate with 79.4% yield after the reaction condition optimization. The intermediate 3 was further reacted with 
isocyanates to form a series of novel 4-substitued-1-(2-methyl-6-(pyridin-3-yl)-nicotinoyl) semicarbazides 4a-r with yields 
range from 43.3% to 82.0%. Ethanol and toluene were investigated as solvents in the synthesis of 4a-r. The yield was better 
and melting point range of compounds was shorter when ethanol was used as solvent. The structures of target compounds 
4a-r were characterized by 
1
H NMR, 
13
C NMR and HRMS. 
 
 
 
 
 
 
 
 
 
Scheme 1 (i) ethyl acetoacetate, acetic acid, ammonium acetate, reflux, 5 h (ii) hydrazine hydrate, ethanol, reflux, 5 h (iii) isocyanates, ethanol, 5 h. 
 
2.2 Antitumor activities 
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The in vitro cytotoxic activity of target compounds 4a-r was evaluated in human cancer lines including QGY-7703, 
NCl-H460 and MCF-7 by the MTT assay, and imatinib was used as the positive control. The concentration required for 50% 
inhibition of cell viability (IC50) was calculated and summarized in Table 1. The IC50 values of compounds 4a and 4b were 
over 100 M for all tested human cancer cell lines, indicating that the introduction of a n-alkyl group that had more than three 
carbon atoms to the pharmaceutical core was unfavorable for anti-proliferative properties. Among the other synthesized 
compounds (4c-r), the cytotoxic activity order is as following: compounds 4n-r bearing multi fluorine or chlo-
rine-substituted phenyl group > compounds 4e-l bearing mono-substituted phenyl group > compounds 4c-d bearing cyclic 
aliphatic group. compound 4n with the substitution of 2,4-difluorophenyl displayed the most potential cytotoxicity with IC50 
value of 8.89 μmol/L against QGY-7703 line. 
In order to test the effect of compound 4n on normal cells, MCR-5 cell line ( human normal lung cell line) and LO2 
cell line (the normal hepatocytes cell line) were used. The results shown that compound 4n has IC50 values for the LO2 cells 
is about 77.65 M and the IC50 values for the MRC-5 cells is about 21.32 M. The results indicated that the normal lung 
cells(MRC-5 cells) and normal hepatocytes cells (LO2 cells) were more resistant to the toxic activity of compound 4n than  
H460 cells and QGY7703 cells. 
 
 
Table 1 The cytotoxicity of target compounds 4a-r against QGY-7703, NCl-H460 and MCF-7 cancer cell lines 
 
 
Compound R IC50 (M) ± S.D. 
QGY7703 H460 MCF7 
4a 
 
>100 >100 >100 
4b  
>100 >100 >100 
4c 
 
55.89±0.98 67.89±0.78 54.78±0.09 
4d 
 
45.80±0.18 64.89±0.20 55.78±0.34 
4e 
 
33.78±0.10 43.89±0.13 34.90±0.20 
4f 
 
33.48±0.40 33.44±0.20 23.96±0.11 
4g 
 
22.45±0.11 31.89±0.34 26.90±0.10 
4h 
 
22.45±0.19 31.89±0.30 26.90±0.19 
4i 
 
23.48±0.11 23.44±0.89 23.80±0.45 
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4j 
 
22.40±0.34 15.89±0.19 16.90±0.45 
4k 
 
22.40±0.32 21.89±0.78 16.50±0.45 
4l 
 
23.89±0.30 21.90±0.34 27.09±0.44 
4m 
 
24.89±0.13 27.80±0.16 24.10±0.45 
4n 
 
8.89±0.20 10.90±0.32 11.45±0.44 
4o 
 
12.80±0.22 12.78±0.12 14.40±0.13 
4p 
 
13.89±0.10 15.60±0.33 15.09±0.20 
4q 
 
14.89±0.23 17.60±0.10 18.10±0.40 
4r 
 
10.60±0.20 11.80±0.30 12.40±0.22 
Imatinib  8.54±0.16 10.78±0.23 9.45±0.22 
 
 
2.3 The effect of 4n on apoptosis in QGY7703 cells 
According to the MTT assay of different compounds, we found that the compound 4n most effectively inhibited cell 
viability in QGY7703 cells, so 4n was selected for further cellular studies. MTT result shown that the 4n had the an-
ti-proliferative activity in QGY7703 cells with the IC50 value 8.89 μM, so firstly, the QGY7703 cells were treated with 4n 
for 24 h with different drug concentrations. After 4n treatment, the cleaved PARP (the mark of apoptosis) was tested. The 
Western blot result shown that after 4n treatment, the cleaved PARP could be observed obviously even at the low drug con-
centration (10 μM) (Figure 2). 
In order to conform that 4n can promote apoptosis in QGY7703 cells, after the 4n treatment for 24 h, the QGY7703 
cells were doubly stained with annexin V/PI (propidium iodide). As the FACS results shown in Figure 3, the compound 4n 
can effectively induce apoptosis in QGY7703 cells in does-dependent manner. 
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Figure 2 Western blot analysis to test the cleaved PARP after 4n treatment in QGY7703 cells and GAPDH was used as internal control. 
 
Figure 3  QGY7703 cells were treated with 4n at the indicated concentrations for 24 h, and stained annexin V/PI. The apoptosis 
was detected by FACS. 
 
3  Conclusions 
A series of 4-substitued-1-(2-methyl-6-(-3-pyridy)-nicotinoyl) semicarbazides were designed and synthesized via mo-
lecular hybridization strategy. The reaction condition was optimized and eighteen target compounds 4a-r were prepared under 
best condition. The structures of target compounds 4a-r were characterized by 
1
H NMR, 
13
C NMR and HRMS. The cytotoxic 
activity in vitro of compounds 4a-r against QGY-7703, NCl-H460, and MCF7 cell lines was evaluated by the MTT assay, and 
compound 4n displayed the most potential cytotoxic activity with IC50 value of 8.89 μmol/L, 10.90 μmol/L, and 11.45 μmol/L 
against QGY-7703, NCl-H460, and MCF7 respectively. The effect of 4n on apoptosis in QGY-7703 cells were detected by 
Western blot and annexin V/PI staining (FACS) and 4n treatment can induce the increase of cleaved PARP and late stage 
apoptosis. 
 
4  Experimental section 
4.1  Materials and instruments 
All chemicals were analytically pure and purchased from commercial sources. All melting points were determined on a 
WRS-1B Digital Melting Point Apparatus (uncorrected). All new compounds were characterized by 
1
H NMR, 
13
C NMR 
and HRMS. NMR spectra were recorded in DMSO-d6 on a Bruker AV 600 MHz instrument. HRMS spectra were obtained 
on a Agilent 6230 mass spectrometer. Human breast cell line MCF-7, human hepatocelular carcinoma cell line QGY-7703 
and non-small cell lung cancer cell line NCl-H460 were purchased from Shanghai Cell Bank, Chinese Academy of Scienc-
es. 
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4.2 Synthesis 
4.2.1 Synthesis of ethyl (2-methyl-6-(-3-pyridy)) nicotinate (2) 
3-(dimethylamino)-1-(pyridin-3-yl)prop-2-en-1-one (1) (5 mmol, 0.88 g), ethyl acetoacetate (5.5 mmol, 0.75 g) and 
ammonium acetate (40 mmol, 0.31 g) were dissolved in acetic acid (15 mL), and the reaction mixture was allowed to reflux 
for 5 h. After completion of reaction, the reaction mixture was cooled down to room temperature, to the reaction mixture 
were added ice cold water (100 mL), the aqueous phase was extracted with ethyl acetate (30 mL) third times, and the com-
bined organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo to afford a residue which was puri-
fied by column (ethyl acetate: petroleum ether = 1:4) to afford the product 2 (0.89 g, 73.5%) as yellow solid. m.p. 
160.2-161.0℃. 1H NMR (600 MHz, DMSO-d6) δ: 9.32 (d, J = 2.02 Hz, 1H), 8.68 (dd, J = 1.65, 4.77 Hz, 1H), 8.53-8.44 (m, 
1H), 8.28 (d, J = 8.25 Hz, 1H), 8.03 (d, J = 8.25 Hz, 1H), 7.55 (dd, J = 4.77, 8.07 Hz, 1H), 4.34 (q, J = 7.09 Hz, 2H), 2.80 
(s, 3H), 1.35 (t, J = 7.06 Hz, 3H).
 13
C NMR (150 MHz, DMSO-d6) δ:166.2, 159.3, 155.9, 151.0, 148.6, 139.8, 134.8, 133.4, 
124.6, 124.2, 118.3, 61.5, 25.1, 14.5. HRMS calcd. for C14H14N2O2: 243.1134 [M+H]
+
; found: 243.1132.  
4.2.2 Synthesis of 6-methyl-[2,3'-bipyridine]-5-carbohydrazide (3) 
Compound 2 (5 mmol, 0.61 g) was dissolved in ethanol (5 mL). To the mixture was added hydrazine hydrate ( 2 mL). 
The reaction mixture was heated under reflux for 5 h. After completion of the reaction, the reaction mixture was cooled 
down to room temperature and precipitated. The solid was filtered off and washed with ethanol, affording the product 3 
(0.91g, 79.4%) as white solid. m.p. 174.2-174.3℃. 1H NMR (600 MHz, DMSO-d6) δ: 9.65 (s, 1H), 9.28 (d, J = 1.83 Hz, 
1H), 8.65 (dd, J = 1.47, 4.77 Hz, 1H), 8.45 (dt, J = 1.79, 7.98 Hz, 1H), 7.94 (d, J = 8.07 Hz, 1H), 7.82 (d, J = 7.89 Hz, 1H), 
7.53 (dd, J = 4.77, 7.89 Hz, 1H), 4.56 (brs, 2H), 2.62 (s, 3H). 
13
C NMR (150MHz, DMSO-d6) δ: 167.5, 156.5, 154.1, 150.6, 
148.4, 137.0, 134.5, 133.9, 130.3, 124.3, 118.0, 23.4. HRMS calcd. for  C12H12N4O: 229.1089 [M+H]
+
; found: 229.1088.  
4.2.3 General procedure for the synthesis of 4-substitued-1-(2-methyl-6-(pyridin-3-yl)- nicotinoyl) semicarbazides (4a-r) 
Compound 3 (5 mmol, 1.14 g) was dissolved in ethanol (10 mL). To the mixture was added different isocyanates (5.5 
mmol). The reaction mixture was heated under reflux for 3 h. After completion of the reaction, the reaction mixture was 
filtered off and washed with ethanol, affording the products 4a-r. 
N-butyl-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4a): white solid, yield: 80.5%. m.p. 
163.6-165.9℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.04 (brs, 1H), 9.30 (brs, 1H), 8.66 (brs, 1H), 8.48 (d, J = 7.15 Hz, 1H), 
7.99 (brs, 2H), 7.95 (brs, 1H), 7.58-7.46 (m, 1H), 6.51 (brs, 1H), 3.17-3.00 (m, 2H), 2.66 (s, 3H), 1.44-1.36(m, 2H), 
1.34-1.23(m, 2H), 0.88 (t, J = 7.15 Hz, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.1, 158.5, 156.9, 154.4, 150.6, 148.4, 
137.4, 134.6, 133.9, 129.6, 124.3, 117.9, 39.4, 32.5, 23.5, 19.9, 14.2. HRMS calcd. for C17H21N5O2: 328.1768 [M+H]
+
; 
found: 328.1767. 
N-heptyl-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4b): white solid, yield: 76.5%. m.p. 
161.8-162.5℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.03 (d, J = 1.83 Hz, 1H), 9.31 (d, J = 1.65 Hz, 1H), 8.66 (dd, J = 1.38, 
4.68 Hz, 1H), 8.48 (dt, J = 1.95, 8.02 Hz, 1H), 8.01-7.98 (m, 2H), 7.94 (s, 1H), 7.61-7.45 (m, 1H), 6.49 (brs, 1H), 3.06 (q, J 
= 6.72 Hz, 2H), 2.67 (s, 3H), 1.50-1.38 (m, 2H), 1.34-1.21 (m, 9H), 0.88-0.85 (m, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 
168.1, 158.6, 156.9, 154.4, 150.7, 148.4, 137.4, 134.6, 133.9, 129.6, 124.3, 117.8, 39.7, 31.8, 30.4, 29.0, 26.8, 23.5, 22.5, 
14.4. HRMS calcd. for C20H27N5O2: 370.2238 [M+H]
+
; found: 370.2240. 
N-cyclopentyl-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4c): white solid, yield: 78.5%. m.p. 
203.3-203.9℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.01 (s, 1H), 9.30 (d, J = 1.83 Hz, 1H), 8.66 (dd, J = 1.65, 4.77 Hz, 1H), 
8.47 (dt, J = 1.86, 8.21 Hz, 1H), 8.00-7.96 (m, 1H), 7.95-7.92 (m, 1H), 7.84 (s, 1H), 7.55 (ddd, J = 0.73, 4.77, 7.89 Hz, 1H), 
6.41 (d, J = 7.52 Hz, 1H), 3.94 (sxt, J = 6.93 Hz, 1H), 2.67 (s, 3H), 1.90-1.76 (m, 2H), 1.69-1.60 (m, 2H), 1.55-1.46 (m, 
2H), 1.44-1.36 (m, 2H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.1, 158.1, 156.8, 154.4, 150.7, 148.4, 137.3, 134.6, 134.5, 
133.9, 129.6, 124.3, 117.9, 51.6, 33.1, 23.7, 23.5. HRMS calcd. for C18H21N5O2: 340.1768 [M+H]
+
; found: 340.1770. 
N-cyclohexyl-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4d): white solid, yield: 82.0%. m.p. 
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216.8-217.1℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.02 (s, 1H), 9.30 (d, J = 1.65 Hz, 1H), 8.66 (dd, J = 1.56, 4.68 Hz, 1H), 
8.47 (dt, J = 1.86, 8.21 Hz, 1H), 8.01-7.96 (m, 1H), 7.95-7.91 (m, 1H), 7.89-7.86 (m, 1H), 7.56-7.53(m, 1H), 6.32 (d, J = 
8.07 Hz, 1H), 3.49-3.41 (m, 1H), 2.67 (s, 3H), 1.83-1.74 (m, 2H), 1.73-1.64 (m, 2H), 1.62-1.48 (m, 1H), 1.32-1.11 (m, 5H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.1, 157.7, 156.8, 154.4, 150.7, 148.4, 137.3, 134.6, 133.9, 129.7, 124.3, 117.9, 48.6, 
33.5, 25.7, 25.1, 23.5. HRMS calcd. for C19H23N5O2: 354.1925 [M+H]
+
; found: 354.1930. 
N-(m-tolyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4e): white solid, yield: 46.6%. m.p. 
217.5-217.6℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.22 (s, 1H), 9.31 (d, J = 1.65 Hz, 1H), 8.84 (brs, 1H), 8.67 (dd, J = 
1.10, 4.58 Hz, 1H), 8.55-8.42 (m, 1H), 8.27 (s, 1H), 8.05-7.95 (m, 2H), 7.55 (dd, J = 4.77, 7.89 Hz, 1H), 7.34 (s, 1H), 7.28 
(d, J = 8.07 Hz, 1H), 7.16 (t, J = 7.79 Hz, 1H), 6.80 (d, J = 7.34 Hz, 1H), 2.70 (s, 3H), 2.28 (s, 3H). 
13
C NMR (150 MHz, 
DMSO-d6) δ:168.2, 156.8, 155.8, 154.5, 150.7, 148.4, 140.0, 138.3, 137.4, 134.6, 133.9, 129.5, 129.0, 124.3, 123.2, 119.5, 
118.0, 116.1, 23.5, 21.7. HRMS calcd. for C20H19N5O2: 362.1612 [M+H]
+
; found: 362.1611. 
N-(p-tolyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4f): white solid, yield: 50.5%. m.p. 
200.5-202.9℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.23 (s, 1H), 9.32 (d, J = 1.47 Hz, 1H), 8.83 (s, 1H), 8.67 (dd, J = 1.28, 
4.59 Hz, 1H), 8.48 (dt, J = 1.86, 8.02 Hz, 1H), 8.26 (s, 1H), 8.06-7.94 (m, 2H), 7.55 (dd, J = 4.77, 7.52 Hz, 1H), 7.39 (d, J = 
8.25 Hz, 2H), 7.09 (d, J = 8.25 Hz, 2H), 2.71 (s, 3H), 2.25 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.3, 156.9, 155.9, 
154.5, 150.7, 148.4, 137.5, 137.3, 134.6, 133.9, 131.2, 129.6, 129.5, 124.3, 119.1, 117.9, 23.5, 20.8. HRMS calcd. for 
C20H19N5O2: 362.1612 [M+H]
+
; found: 362.16416. 
N-(3-fluorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4g): yellow solid, yield: 
61.2%. m.p. 224.5-225.5℃. 1H NMR (600 MHz, DMSO-d6) δ:10.29 (s, 1H), 9.33 (d, J = 1.65 Hz, 1H), 9.21 (brs, 1H), 8.68 
(dd, J = 1.47, 4.58 Hz, 1H), 8.53-8.42 (m, 2H), 7.97-8.07 (m, 2H), 7.62-7.48(m, 2H), 7.35-7.29 (m, 1H), 7.25 (d, J = 7.52 
Hz, 1H), 6.81 (dt, J = 1.83, 8.44 Hz, 1H), 2.72 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.2, 162.8 (d, J=240.0 Hz), 
162.0, 156.9, 155.7, 154.6, 150.7, 148.4, 142.0 (d, J=2.3 Hz), 137.3, 134.6, 133.9, 130.7 (d, J=2.3 Hz), 129.4, 124.3, 118.0, 
114.7, 108.7 (d, J=10.5 Hz), 105.6 (d, J=14.3.0 Hz), 23.5. HRMS calcd. for C19H16FN5O2: 366.1361 [M+H]
+
; found: 
366.1370. 
N-(4-fluorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4h): yellow solid, yield: 
64.5%. m.p. 232.2-232.5℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.26 (s, 1H), 9.33 (d, J = 1.83 Hz, 1H), 9.01 (brs, 1H), 8.68 
(dd, J = 1.47, 4.77 Hz, 1H), 8.49 (dt, J = 1.81, 8.11 Hz, 1H), 8.37 (s, 1H), 8.02 (s, 2H), 7.59-7.50 (m, 3H), 7.19-7.09 (m, 
2H), 2.72 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.3,157.3 (d, J=202.0 Hz),157.1, 156.9, 157.3, 154.5, 150.7, 148.4, 
137.3, 136.4 (d, J=2.2 Hz),134.6, 133.9, 129.4, 124.3, 120.8, 117.9, 115.6 (d, J=21.0 Hz), 23.5. HRMS calcd for 
C19H16FN5O2: 366.1361 [M+H]
+
; found: 366.1370. 
N-(4-chlorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4i): white solid, yield: 56.2%. 
m.p. 229.6-230.5℃. 1H NMR (600 MHz, DMSO-d6) δ : 10.25 (s, 1H), 9.32 (d, J = 1.65 Hz, 1H), 9.10 (brs, 1H), 8.67 (dd, J 
= 1.56, 4.68 Hz, 1H), 8.49 (dt, J = 1.90, 8.12 Hz, 1H), 8.41 (s, 1H), 8.04-7.98 (m, 2H), 7.58-7.53 (m, 3H), 7.36-7.31 (m, 
2H), 2.71 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.2, 156.9, 155.8, 154.5, 150.7, 148.4, 139.1, 137.3, 134.6, 133.9, 
129.4, 129.0, 126.0, 124.3, 120.5, 118.0, 23.5. HRMS calcd. for C19H16ClN5O2: 382.1065 [M+H]
+
; found: 382.1069. 
N-(3-chlorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4j): white solid, yield: 58.4%. 
m.p. 230.2-230.5℃. 1H NMR (600 MHz, DMSO-d6) δ : 10.27 (s, 1H), 9.32 (d, J = 1.83 Hz, 1H), 9.17 (brs, 1H), 8.68 (dd, J 
= 1.47, 4.77 Hz, 1H), 8.52-8.44(m, 2H), 8.05-7.98 (m, 2H), 7.75 (t, J = 1.93 Hz, 1H), 7.57-7.54 (m, 1H), 7.39 (d, J = 7.15 
Hz, 1H), 7.31 (t, J = 8.07 Hz, 1H), 7.08-6.98 (m, 1H), 2.71 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ:168.2, 156.9, 155.7, 
154.6, 150.7, 148.4, 141.7, 137.4, 134.6, 133.8, 133.6, 130.8, 129.4, 124.3, 122.0, 118.3, 118.0, 117.4, 23.5 . HRMS calcd. 
for C19H16ClN5O2: 382.1065 [M+H]
+
 ; found: 382.1070. 
N-(2-chlorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4k): white solid, yield: 58.9%. 
m.p. 227.8-228.5℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.40 (s, 1H), 9.32 (d, J = 1.65 Hz, 1H), 9.06 (brs, 1H), 8.68 (dd, J 
= 1.47, 4.77 Hz, 1H), 8.49 (dt, J = 1.88, 8.16 Hz, 1H), 8.40 (brs, 1H), 8.14 (d, J = 8.07 Hz, 1H), 8.04-8.01(m, 1H), 
8.00-7.97(m, 1H), 7.57-7.54 (m, 1H), 7.48 (dd, J = 1.38, 7.98 Hz, 1H), 7.35-7.30 (m, 1H), 7.06 (dt, J = 1.38, 7.66 Hz, 1H), 
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2.71 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.2, 156.7, 155.4, 154.6, 150.7, 148.4, 137.3, 136.2, 134.6, 133.8, 129.7, 
129.3, 128.1, 124.3, 124.1, 121.9, 118.0, 23.4. HRMS calcd. for C19H16ClN5O2: 382.1065 [M+H]
+
; found: 382.1070. 
N-(4-methoxyphenyl)-2-(6-methyl-[2,3'-bipyrdine]-5-carbonyl)hydrazine-1-carboxamide (4l): white solid, yield: 
49.0%. m.p. 222.6-223.2℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.20 (d, J = 0.92 Hz, 1H), 9.32 (d, J = 1.65 Hz, 1H), 8.75 
(s, 1H), 8.67 (dd, J = 1.38, 4.68 Hz, 1H), 8.52-8.43 (m, 1H), 8.22 (s, 1H), 8.04-7.94 (m, 2H), 7.55 (dd, J = 4.77, 7.89 Hz, 
1H), 7.40 (d, J = 8.99 Hz, 2H), 6.88 (d, J = 9.17 Hz, 2H), 3.72 (s, 3H), 2.70 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ:  
168.3, 156.9, 156.1, 155.0, 154.5, 150.7, 148.4, 137.4, 134.6, 133.9, 133.1, 129.5, 124.3, 120.8, 117.9, 114.3, 55.6, 23.5. 
HRMS calcd. for C20H19N5O3: 378.1561 [M+H]
+ 
; found: 378.1565. 
N-(3,5-dimethylphenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4m): white solid, yield: 
66.5%. m.p. 229.6-230.0℃. 1H NMR (600MHz, DMSO-d6) δ: 10.22 (s, 1 H), 9.32 (d, J=1.7 Hz, 1 H), 8.76 (brs, 1 H), 8.67 
(dd, J=4.6, 1.3 Hz, 1 H), 8.54-8.41 (m, 1 H), 8.25 (s, 1 H), 8.04-7.95 (m, 2 H), 7.55 (dd, J=7.7, 4.8 Hz, 1 H), 7.13 (s, 2 H), 
6.62 (s, 1 H), 2.71 (s, 3 H), 2.24 (s, 6 H). 
13
C NMR (150 MHz, DMSO-d6) δ:168.2, 156.8, 155.8, 154.5, 150.7, 148.4, 139.9, 
138.1, 137.4, 134.6, 133.9, 129.5, 124.3, 124.0, 118.0, 116.7, 23.5, 21.6. HRMS calcd. for C21H21N5O2: 376.1768 [M+H]
+
; 
found: 376.1769. 
N-(2,4-difluorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4n): white solid, yield: 
66.7%. m.p. 291.9-293.6℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.35 (s, 1H), 9.32 (d, J = 1.83 Hz, 1H), 8.72 (brs, 1H), 8.68 
(dd, J = 1.47, 4.77 Hz, 1H), 8.60 (s, 1H), 8.49 (dt, J = 1.90, 8.12 Hz, 1H), 8.05-7.96 (m, 3H), 7.57-7.54 (m, 1H), 7.35-7.31 
(m, 1H), 7.11-7.02 (m, 1H), 2.71 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.2, 158.5 (d, J=256.5 Hz), 156.8, 155.7, 
154.6, 150.7, 148.4, 137.3, 134.6, 133.8, 129.4, 124.3, 118.0, 111.6, 111.4, 104.5, 104.3 (d, J=2.2 Hz), 104.2, 23.4. HRMS 
calcd. for C19H15F2N5O2: 384.1267 [M+H]
+ 
; found: 384.1270. 
N-(3,4-difluorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4o): white solid, yield: 
60.0%. m.p. 224.0-224.3℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.28 (s, 1H), 9.33 (d, J = 1.47 Hz, 1H), 9.21 (brs, 1H), 8.68 
(dd, J = 1.19, 4.68 Hz, 1H), 8.54-8.46(m, 2H), 8.06-7.99 (m, 2H), 7.74-7.70 (m, 1H), 7.56 (dd, J = 4.77, 7.89 Hz, 1H), 
7.39-7.32 (m, 1H), 7.27 (brs, 1H), 2.72 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.3, 156.9 (d, J=256.5 Hz), 155.8, 
154.6, 150.7, 149.5 (dd, J=13.3, 229.5 Hz), 148.4, 145.0 (dd, J=13.3, 232.5 Hz), 134.6, 134.2, 133.8, 129.4, 124.3, 117.9, 
117.8, 117.7, 115.1, 107.9, 23.5. HRMS calcd. for C19H15F2N5O2: 384.1267 [M+H]
+
; found: 384.1271. 
N-(3-chloro-4-fluorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4p): white solid, 
yield: 43.3%. m.p. 238.3-238.6℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.27 (s, 1H), 9.33 (d, J = 1.65 Hz, 1H), 9.18 (brs, 
1H), 8.68 (dd, J = 1.56, 4.68 Hz, 1H), 8.52 (s, 1H), 8.49 (dt, J = 1.88, 8.16 Hz, 1H), 8.12-7.97 (m, 2H), 7.85 (dd, J = 2.57, 
6.79 Hz, 1H), 7.57-7.54 (m, 1H), 7.43 (brs, 1H), 7.39-7.30 (m, 1H), 2.72 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 168.3, 
156.4 (d, J=220.0 Hz), 154.6, 153.7, 152.1, 150.7, 148.4, 137.5, 137.4 (d, J=3.0 Hz), 134.6, 133.8, 129.4, 124.3, 120.3, 
119.6, 119.4, 119.3, 117.9, 117.2 (d, J=10.5 Hz), 23.5. HRMS calcd. for C19H15ClFN5O2: 400.0971 [M+H]
+
; found: 
400.0973. 
N-(3,4-dichlorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4q): white solid, yield: 
49.9%. m.p. 204.0-204.9℃. 1H NMR (600 MHz, DMSO-d6) δ: 10.28 (s, 1H), 9.32 (d, J = 1.65 Hz, 1H), 9.29 (d, J = 1.65 
Hz, 1H), 8.68 (dd, J = 1.65, 4.77 Hz, 1H), 8.58 (s, 1H), 8.49 (dt, J = 1.79, 8.16 Hz, 1H), 8.06-7.98 (m, 2H), 7.94-7.90 (m, 
1H), 7.57-7.54(m, 1H), 7.54-7.52 (m, 1H), 7.47 (d, J = 6.79 Hz, 1H), 2.71 (s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ: 
168.2, 156.9, 155.7, 154.6, 150.7, 148.4, 140.4, 137.4, 134.6, 133.8, 131.4, 131.0, 129.3, 124.3, 123.7, 120.1, 119.1, 118.0,  
23.5. HRMS calcd. for C19H15Cl2N5O2: 416.0603 [M+H]
+
; found: 416.0606. 
N-(2,4,6-trichlorophenyl)-2-(6-methyl-[2,3'-bipyridine]-5-carbonyl)hydrazine-1-carboxamide (4r): white solid, yield: 
45%. m.p.  230.0-231.5℃. 1H NMR (600 MHz, DMSO-d6) δ:10.30 (brs, 1H), 9.31 (d, J = 1.83 Hz, 1H), 8.69-8.63 (m, 
2H), 8.60 (brs, 1H), 8.48 (dt, J = 1.90, 8.12 Hz, 1H), 8.00 (d, J = 7.70 Hz, 1H), 7.76-7.71 (m, 2H), 7.55-7.53 (m, 1H), 2.67 
(s, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ:168.0, 157.0, 154.5, 150.7, 150.5, 148.4, 148.3, 137.4, 135.7, 134.6, 134.5, 
133.8, 133.5, 132.1, 129.4, 128.6, 128.5, 124.3, 117.9, 23.5. HRMS calcd. for C19H14N5O2: 450.0286 [M+H]
+
; found: 
450.0284. 
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4.3 MTT toxicity assay 
 
The in vitro antiproliferative activity of target compounds 4a-r against three human cancer lines including QGY-7703, 
NCl-H460 and MCF-7 cancer cell lines was measured by the MTT colorimetric method 
[16-18]
. In all experiments, cells in 
good condition and logarithmic growth phase were taken and digested by 0.25% trypsin. The adherent cells were detached 
and counted, a 2-4*10
4
 cells/mL suspension was prepared and inoculated into 96-well cell culture plate with 180 μL a well, 
placed in constant temperature carbon dioxide incubator and cultured for 24 h, then was replaced with the dimethyl sulfox-
ide (DMSO) solution of target compound (20 μL) a well, and added 10 vol% serum culture medium (80 μL), and cultured 
for 48 h. MTT (20 μL) was added to each well and reacted for 4 h. The supernatant was removed and DMSO (150 μL per 
well) was added to dissolve MTT. The plate was shaken on platform rocker for five minutes, and the optical density (OD) of 
each well was measured on enzyme-linked immunosorbent assay (ELISA) meter at the wavelength of 570 nm. The inhibi-
tion activity of cell proliferation was determined. Dissolvent control group was used as negative control group, and 
4-substitued-1-(2-methyl-6-(pyridin-3-yl)-nicotinoyl) semicarbazides was used as positive control group. The inhibition rate 
of target compounds on tumor cell growth was calculated according to the following formula:inhibition rate%=[(OD value 
of the negative control-OD value of tested compound)/ OD value of the negative control×100%. The IC50 value of target 
compounds was calculated based on the inhibition rates of different concentrations. 
4.4 Annexin V/PI staining 
 
Cells were cultured in six-well with about 1×105 cells in each well and treated with varying concentrations of 4n for 
24 h. Then the apoptosis analysis was performed following the protocols (BD Bioscience). After stained with FITC annexin 
V/PI, the apoptosis status was analyzed using a Beckman Epics Altra Culter and data were analyzed with EXP032 software. 
The status and percentage of cells undergoing apoptosis was defined as early apoptosis (annexin V-positive and PI-negative) 
and late apoptosis (annexin V- positive and PI-positive). 
4.5 Western blot analysis 
 
To check the level of cleaved PARP1 after 4n treatment, the Western blot were performed  using PARP1 antibody 
(9542, CST, Shanghai, China), meanwhile the GAPDH antibody (G8795, Sigma) was used as control. After 4n treatment for 
24 h, the whole cells lysates were used for Western blot analysis. Both anti-rabbit and anti-mouse IgG were purchased from 
Sigma. 
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A series of 4-substitued-1-(2-methyl-6-(-3-pyridy)-nicotinoyl) semicarbazides 
4a-r were designed and synthesized. Compound 4n displayed the most potential cyto-
toxicity against all tested cell lines. 
 
